Genmab — November 2024
-
small new (sub)trial - Epcoritamab in Chronic Lymphocytic Leukemia and Richter Syndrome
https://clinicaltrials.gov/study/NCT06676033 -
https://www.fiercepharma.com/pharma/drugs-unmet-needs-and-those-experienced-companies-have-best-chance-successful-launches Genmab and AbbVie’s debut of Epkinly for patients with diffuse large B-cell lymphoma has also exceeded expectations in its battle with
Columvi. -
“The company’s go-to-market strategy focused on leveraging the first-mover advantage with a focus on key accounts and customers, utilizing field medical, sales and market access teams across both Genmab and AbbVie,” Trinity wrote. “Genmab and AbbVie’s combined experience in hematology-oncology certainly helped navigate the early diagnosis, treatment and reimbursement realities inherent in complex new therapies of this type.”
-
@Sukkeralf - Uanset, må det være jo før jo bedre at få en afklaring..... @Solsen du mener det er US der handler aktien ned - Hvordan får du den opfattelse.... Jeg synes at have set at det er US der handler aktien op og DK der handler den ned?
det ser rigtig fint ud, hvis vi kan holde AE's nede. Kæmpe markedet med 50/50 ejerskab 
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind